41 results about "FLT3 Inhibitor" patented technology

The invention discloses two newly-discovered Flt3 phosphorylation sites, tyrosine 589 (Tyr589) and tyrosine 591 (Tyr591) in the intracellular domain, and provides antibodies, both polyclonal and monoclonal, that selectively bind to Flt3 when phosphorylated at these novel sites. Also provided are assays utilizing these reagents, including methods for determining the phosphorylation of Flt3 in a biological sample, selecting a patient suitable for Flt3 inhibitor therapy, profiling Flt3 activation in a test tissue, and identifying a compound that modulates phosphorylation of Flt3 in a test tissue, by using a detectable reagent, such as the disclosed antibodies, that binds to Flt3 when phosphorylated at Tyr589 or Tyr591. The sample or test tissue may be taken from a subject suspected of having cancer, such as acute myelogenous leukemia (AML).

New methods are provided for suppressing the immune system and for treating immune related disorders. Therapies of the invention include administration of an FLT3 inhibitor compound to a subject in need thereof, such as a subject suffering from organ rejection, bone marrow transplant rejection, acquired immune deficiency syndrome, arthritis, aplastic anemia, graft-versus-host disease, Graves' disease, established experimental allergic encephalitomyelitis, multiple sclerosis, lupus, or a neurological disorder. Methods are also provided for screening therapeutic agents for treating immune disorders, including the use of a mouse having an elevated level of FLT3 receptor activity.

Provided are a pteridine ketone derivative used as an EGFR, BLK, and FLT3 inhibitor and applications thereof. Specifically, provided are a compound of the following formula I, a pharmaceutical composition containing the compound of the formula I, and use of compound in preparing medicine for treating diseases mediated by EGFR, BLK, or FLT3 or inhibiting EGFR, BLK, and FLT3.

The invention relates to a pteridinone derivative used as an FLT3 inhibitor, and an application thereof, and concretely relates to a compound represented by formula I, a medicinal composition containing the compound of formula I, and a use of the compound in the preparation of medicines for treating FLT3 mediated diseases or inhibiting the FLT3.

The invention relates to pteridinone derivatives as FLT3 inhibitors and a use thereof. The invention relates to a compound shown in the formula I, a pharmaceutical composition containing the compound shown in the formula I and a use of the compound in preparation of drugs for treating FLT3-mediated diseases or inhibiting FLT3.

The invention discloses a newly discovered Flt3 phosphorylation site, tyrosine 969 (Tyr969) in the intracellular domain, and provides reagents, including polyclonal and monoclonal antibodies, that selectively bind to Flt3 when phosphorylated at this site. Also provided are assays utilizing this reagent, including methods for determining the phosphorylation of Flt3 in a biological sample, selecting a patient suitable for Flt3 inhibitor therapy, profiling Flt3 activation in a test tissue, and identifying a compound that modulates phosphorylation of Flt3 in a test tissue, by using a detectable reagent, such as the disclosed antibody, that binds to Flt3 only when phosphorylated at Tyr969. The sample or test tissue may be taken from a subject suspected of having cancer, such as acute myelogenous leukemia (AML).

Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I).

Compounds of formula

wherein the residues R1, R2, R3, R9, R10 and Q and X, Y and Z are as defined in the specification, salts thereof; their use, methods of their use, processes for their production, pharmaceutical compositions comprising them, their combinations with second drug substances and the use thereof and the like. The compounds are protein kinase inhibitors and can be used for the treatment of diseases mediated by protein kinase inhibitors, e.g. for the treatment of various proliferative diseases.

This invention relates to treatment of cancer using a antibody drug conjugates that comprise PBD molecules in combination with FLT3 inhibitors.

The invention discloses a 5-position ring substituted 2, 4-diaminopyrimidine compound with phenylglycinol structure, preparation and application thereof. The structure of the compound provided by theinvention is shown as general formula I, and the definitions of all substituent groups are described as the specification and claims. The compound shows remarkable inhibitory activity on Tel-BaF3-FLT3and BaF3-FLT3-ITD mutant cells, shows weak activity on Tel-BaF3-cKIT cells, and has good selectivity, thus being a very potential FLT3 inhibitor.

The invention discloses application of erlotinib in preparation of an FLT3 inhibitor-type medicine and further discloses application of erlotinib in preparation of a medicine for treating leukemia. The erlotinib can inhibit the enzyme activity of FLT3, has an extremely-high inhibition function on FLT3-ITD mutant-type leukemia cells, has a good function of inhibiting leukemia in vivo, can have an inhibition function under the condition of a low side effect and is good in clinical application prospect.

The invention relates to a novel 4-(aromatic heterocyclic substituted)amino-1H-3-pyrazolecarboxamide compound or pharmaceutically acceptable salts, solvates, isomers, esters, acids, metabolites or pro-drugs thereof and a preparation method thereof. The invention provides medical compositions comprising the compounds and medical application thereof.

The present invention relates to small molecule compounds of formula (I) and their use as FLT3 inhibitors for the treatment of various diseases, such as acute myeloid leukemia (AML). The present invention further relates to methods of synthesizing the compounds and methods of treatment.

The invention discloses a CDK4-FLT3 inhibitor and an application of the CDK4-FLT3 inhibitor. The compound is a compound shown as a formula I, and pharmaceutically acceptable salt, hydrate, solvate, metabolite, stereoisomer, tautomer or prodrug thereof. The compound can be used for preparing medicines for treating and/or preventing cancers.

The invention belongs to the technical field of biological medicines, and relates to a pharmaceutical composition containing arsenic trioxide (ATO) and an application thereof, in particular to a pharmaceutical composition containing arsenic trioxide and an FLT3 inhibitor and an application of the pharmaceutical composition in preparation of medicines for treating leukemia, in particular to the application of a pharmaceutical composition of arsenic trioxide and an FLT3 inhibitor (midostaurin), sorafenib, gilteritinib, crenolanib or quizartinib in preparation of a medicine for treating AML withFLT3-ITD mutation. Wherein the molar ratio of arsenic trioxide to perindopril to sorafenib to gilteritinib is 100: 1-5: 1, the molar ratio of arsenic trioxide to crenolanib is 100: 1-5: 1, and the molar ratio of arsenic trioxide to quizartinib is 1000: 1-50: 1. The composition disclosed by the invention can selectively induce apoptosis of AML cells subjected to FLT3-ITD mutation, and can be used for treating leukemia.

The invention generally relates to the treatment of cancer with FLT3 targeting agents and kinase inhibitors. In particular, the invention relates to adoptive immunotherapy of Acute Myeloid Leukemia (AML) with chimeric antigen receptor (CAR)-modified T cells specific for FMS-like tyrosine kinase (FLT3) in combination with FLT3 inhibitors.